Wu Yali, Liu Yali, Lu Junfeng, Cao Zhenhuan, Jin Yi, Ma Lina, Geng Nan, Ren Shan, Zheng Yanhong, Shen Chengli, Chen Xinyue
International Medical Department, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Division of Surgical Oncology, James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Clin Gastroenterol Hepatol. 2020 Feb;18(2):514-516.e2. doi: 10.1016/j.cgh.2019.04.020. Epub 2019 Apr 10.
Hepatitis B surface antigen (HBsAg) seroclearance has been recommended as an optimal endpoint of antiviral treatment by the latest chronic hepatitis B management guideline. However, few reports investigated the durability of response after HBsAg seroclearance, because of a lower HBsAg seroclearance rate and the difficulty of obtaining a sufficient number of samples for analysis. Our center has made a long-term commitment to investigate the personalized antiviral therapy for chronic hepatitis B. More than 300 patients achieved HBsAg seroclearance by interferon (IFN)-based antiviral treatment. In this study, the durability and the effects of hepatitis B virus (HBV) surface antibody (Anti-HBs) level on relapse after HBsAg seroclearance were investigated.
最新的慢性乙型肝炎管理指南推荐乙肝表面抗原(HBsAg)血清学清除作为抗病毒治疗的最佳终点。然而,由于HBsAg血清学清除率较低且难以获得足够数量的样本进行分析,很少有报告研究HBsAg血清学清除后反应的持久性。我们中心长期致力于研究慢性乙型肝炎的个体化抗病毒治疗。超过300例患者通过基于干扰素(IFN)的抗病毒治疗实现了HBsAg血清学清除。在本研究中,我们调查了HBsAg血清学清除后反应的持久性以及乙肝病毒(HBV)表面抗体(抗-HBs)水平对复发的影响。